ins-$0.7M · 13F 16+/7-×0.0 · short↑0.25
Current snapshotPublic companyResearch currentFresh
Emergent BioSolutions Inc.
Package & Deliver · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Package & Deliver exposure in Healthspan Infrastructure.
- **EBS — Emergent BioSolutions Inc.** — Operates fill-finish CDMO capacity; its SEC filings disclose capacity and viral-manufacturing risk. [SEC EDGAR](https:/
Catalysts
Q3 2026 results and conference call Mon Nov 2, 2026, 5:00pm ET (company release). Sept 1, 2026: awarded a contract modification valued at ~$24M from BARDA (ASPR/HHS) to supply CYFENDUS anthrax vaccine (Anthrax Vaccine Adsorbed, Adjuvanted) for national preparedness, produced from domestic manufacturing. [SEC 8-K EX-99.1 9/1/26; EBS investor release]
Invalidation
needs primary source validation — pending deep-dive research. Placeholder: (1) thesis chain breaks on primary-source evidence, (2) named revenue/customer concentration risk, (3) margin compression or competitive displacement
Latest change
· Coverage moved from — to Added to coverage.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
needs primary source validation — no X/Reddit signal yet
Lower-confidence snapshotTarget price: $15.00
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Toll Road Tier
- Weak proxy
Timestamped research update
Deep research update
2,631 words · Updated 19 Oct 2026 · 9 sources
Emergent BioSolutions Inc. is a US-listed company materially exposed to Sterile Fill-Finish Capacity Economics.
Emergent BioSolutions Inc. is a specialty biopharmaceutical company focused on medical countermeasures, public-health threats, and opioid-overdose reversal. Its filings and investor disclosures typically describe three revenue-producing business lines:
| Business line | Primary products / activities | Revenue mix claim |
|---|---|---|
| Commercial Products | NARCAN (naloxone HCl) Nasal Spray | needs primary source validation |
| Medical Countermeasures (“MCM”) Products | BioThrax, AV7909/NuThrax, ACAM2000, VIGIV, BAT, Anthrasil, other biodefense products | needs primary source validation |
| Services / CDMO | Contract development and manufacturing, fill-finish, process development | needs primary source validation |
Source path: SEC EDGAR company filing index for EBS, Form 10-K filings,
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367644&type=10-K&dateb=&owner=include&count=40
Accessed 2026-04-26. Document ID: most recent EBS Form 10-K; accession number not retrieved.
I am intentionally not stating a precise segment percentage because I could not retrieve the actual 10-K segment footnote. Any percentage published here without retrieval would risk fabrication. To complete this block, pull the FY2024 Form 10-K “Segment Information” note and the MD&A revenue discussion.
Emergent’s monetization is contract-driven rather than a traditional unit-priced biotech model.
- U.S. government procurement: The company sells vaccines, antitoxins, and immune globulins to HHS, BARDA, the Department of Defense, and other government entities under multi-year procurement and development contracts. Revenue often depends on product delivery, stockpile acceptance, and government appropriations rather than purely unit demand.
- Commercial distribution: NARCAN is sold through wholesalers and retail pharmacies, now largely as an over-the-counter opioid-overdose reversal product. The commercial economics are more traditional: gross-to-net pricing, returns, chargebacks, and wholesaler fees.
- CDMO services: Emergent earns fee-for-service revenue from development and manufacturing agreements, including technology transfer, process validation, drug substance manufacturing, fill-finish, and sometimes termination fees. This business is utilization-dependent and can be volatile.
Who pays ultimately:
- Federal government: HHS, BARDA, CDC, DoD, and potentially VA.
- State/local governments and first-responder agencies: naloxone distribution programs, police/fire/EMS purchases.
- Wholesalers, pharmacies, and payers: NARCAN commercial channel.
- Biopharmaceutical clients: CDMO customers.
Top customers named in prior Emergent filings include the U.S. Department of Health and Human Services and the U.S. Department of Defense. During the COVID-19 era, Emergent also named Janssen Pharmaceuticals, Inc. and AstraZeneca as CDMO counterparties. I could not re-verify current customer-concentration percentages or exact names from the latest 10-K without live EDGAR access; those must be pulled from the “Customer Concentration” note.
Source path: SEC EDGAR EBS Form 10-K index,
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367644&type=10-K&dateb=&owner=include&count=40
Accessed 2026-04-26. Document ID: most recent EBS Form 10-K; accession number not retrieved. All customer names above are needs primary source validation for current-filing accuracy.
Exact gross margin, operating margin, and net margin are needs primary source validation. The right source is the FY2024 Form 10-K income statement and segment-level margin disclosures.
Directionally, the business has three margin profiles:
- MCM products: Can carry relatively high gross margins when government contracts cover fixed manufacturing overhead, but margins are lumpy because delivery timing, mix, and inventory write-downs matter.
- Commercial NARCAN products: Gross margins were historically attractive, but generic naloxone competition and OTC-channel pricing pressure likely compress realized price and margin.
- CDMO services: Margin is highly utilization-dependent; excess capacity and fixed-cost absorption are the central issue. Underutilized plants can turn a nominal revenue stream into a loss-making one.
No margin figure is stated here because none was retrievable from a primary source during generation.
Because live primary-source inputs were unavailable, this calculation is explicitly illustrative. It shows the structure and sensitivity of the NARCAN economics; it is not an earnings forecast.
Formula:
\[
Gross\ profit\ per\ carton = realized\ revenue\ per\ carton - COGS\ per\ carton
\]
\[
COGS\ per\ carton = realized\ revenue\ per\ carton \times (1 - gross\ margin)
\]
Assumed inputs:
| Parameter | Value | Source / status |
|---|---|---|
| NARCAN realized revenue per carton | $40.00 | Author assumption; not primary-verified |
| NARCAN gross margin | 60% | Author assumption; not primary-verified |
| Annual fixed cost absorbed by NARCAN franchise | $200.0 million | Author assumption; not primary-verified |
Derived outputs:
| Calculation | Formula | Result |
|---|---|---|
| COGS per carton | $40.00 × (1 − 60%) | $16.00 |
| Gross profit per carton | $40.00 − $16.00 | $24.00 |
| Breakeven cartons | $200.0 million ÷ $24.00 | 8.33 million cartons |
Sensitivity:
| Scenario | Realized $/carton | Gross margin | GP/carton | Breakeven cartons |
|---|---|---|---|---|
| Base case | $40.00 | 60% | $24.00 | 8.33 million |
| Price compression | $30.00 | 60% | $18.00 | 11.11 million |
| Margin compression | $40.00 | 50% | $20.00 | 10.00 million |
| Severe generic pressure | $25.00 | 50% | $12.50 | 16.00 million |
Interpretation: If NARCAN realized price falls toward $25 per carton and gross margin declines to 50%, the franchise requires roughly double the base-case volume to cover $200 million in fixed costs. This is the core risk from generic naloxone entry.
Source for the method: SEC EDGAR EBS Form 10-K index as the intended data path for franchise revenue and gross margin,
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367644&type=10-K&dateb=&owner=include&count=40
Accessed 2026-04-26. Document ID: most recent EBS Form 10-K; accession number not retrieved. Revenue, volume, margin, and fixed-cost inputs are assumed, not measured.
This calculation illustrates why Emergent’s CDMO plant utilization is a load-bearing variable.
Formula:
\[
Contribution\ per\ batch = revenue\ per\ batch - variable\ cost\ per\ batch
\]
\[
Breakeven\ batches = total\ fixed\ cost \div contribution\ per\ batch
\]
\[
Breakeven\ utilization = breakeven\ batches \div total\ annual\ batch\ capacity
\]
Assumed inputs:
| Parameter | Value | Source / status |
|---|---|---|
| Annual batch capacity | 30 batches | Author assumption |
| Revenue per batch | $2.0 million | Author assumption |
| Variable cost per batch | $1.2 million | Author assumption |
| Annual fixed cost | $30.0 million | Author assumption |
Derived:
| Calculation | Formula | Result |
|---|---|---|
| Contribution per batch | $2.0m − $1.2m | $0.8 million |
| Breakeven batches | $30.0m ÷ $0.8m | 37.5 batches |
| Breakeven utilization | 37.5 ÷ 30 | 125% of capacity |
At these assumptions, the line cannot break even at full capacity because pricing does not cover fixed costs plus variable costs. If revenue per batch rose to $2.5 million, contribution per batch becomes $1.3 million, and breakeven utilization falls to:
\[
30.0m \div 1.3m = 23.08\ batches
\]
\[
23.08 \div 30 = 76.9\%
\]
This shows the CDMO business is highly sensitive to pricing and plant utilization.
Source for intended data path: SEC EDGAR EBS Form 10-K index,
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367644&type=10-K&dateb=&owner=include&count=40
Accessed 2026-04-26. Document ID: most recent EBS Form 10-K; accession number not retrieved. Inputs are assumed, not sourced.
- U.S. federal government: HHS, BARDA, CDC, DoD, and potentially other agencies. This is the dominant MCM buyer.
- State, local, and tribal governments: Opioid-overdose response programs, public-health departments, and first responders purchase NARCAN.
- Wholesalers and retail pharmacies: NARCAN’s commercial distribution channel.
- Biopharmaceutical clients: CDMO customers seeking development and manufacturing capacity.
- International governments and allied nations: Some products are sold to non-U.S. government customers.
The following names have appeared in Emergent’s prior SEC filings as material contract or customer relationships:
- U.S. Department of Health and Human Services
- Biomedical Advanced Research and Development Authority
- U.S. Department of Defense
- Janssen Pharmaceuticals, Inc.
- AstraZeneca
These names are needs primary source validation for the current filing period. The current Form 10-K “Customer Concentration” note should identify the exact customers exceeding 10% of revenue and the applicable percentages.
Source path: SEC EDGAR EBS Form 10-K index,
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367644&type=10-K&dateb=&owner=include&count=40
Accessed 2026-04-26. Document ID: most recent EBS Form 10-K; accession number not retrieved.
The U.S. government has historically been a large customer. If one or two government contracts are delayed, canceled, or renegotiated, revenue can fall materially. Customer concentration is a load-bearing risk for Emergent’s countermeasures franchise. Exact concentration percentages are needs primary source validation.
- EBS — Emergent BioSolutions Inc. — Operates fill-finish CDMO capacity; its SEC filings disclose capacity and viral-manufacturing risk. [SEC EDGAR](https:/
- - EBS — Emergent BioSolutions Inc. — Operates fill-finish CDMO capacity; its SEC filings disclose capacity and viral-manufacturing risk. [SEC EDGAR](https:/ source
| Parameter | Value | Source / document ID | Tier | Measured / derived / assumed | Cross-verified |
|---|---|---|---|---|---|
| NARCAN realized revenue per carton | $40.00 | Author assumption; intended data path: SEC EDGAR EBS 10-K index, https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367644&type=10-K&dateb=&owner=include&count=40, accessed 2026-04-26, accession not retrieved | n/a | Assumed | No |
| NARCAN gross margin | 60% | Author assumption; same intended data path | n/a | Assumed | No |
| Annual NARCAN fixed cost | $200.0 million | Author assumption | n/a | Assumed | No |
| COGS per carton | $16.00 | Derived: $40.00 × (1 − 60%) | n/a | Derived | No |
| Gross profit per carton | $24.00 | Derived: $40.00 − $16.00 | n/a | Derived | No |
| NARCAN breakeven cartons | 8.33 million | Derived: $200.0m ÷ $24.00 | n/a | Derived | No |
| CDMO batch capacity | 30 batches/year | Author assumption | n/a | Assumed | No |
| CDMO revenue per batch | $2.0 million | Author assumption | n/a | Assumed | No |
| CDMO variable cost per batch | $1.2 million | Author assumption | n/a | Assumed | No |
| CDMO annual fixed cost | $30.0 million | Author assumption | n/a | Assumed | No |
| CDMO contribution per batch | $0.8 million | Derived: $2.0m − $1.2m | n/a | Derived | No |
| CDMO breakeven utilization | 125% of capacity | Derived: $30.0m ÷ $0.8m = 37.5 batches; 37.5 ÷ 30 | n/a | Derived | No |
| U.S. government customer concentration | needs primary source validation | SEC EDGAR EBS Form 10-K customer concentration note; accession not retrieved | Tier 1 path | Measured, unretrieved | No |
| FY2024 total revenue | needs primary source validation | SEC EDGAR EBS Form 10-K; accession not retrieved | Tier 1 path | Measured, unretrieved | No |
| FY2024 gross margin | needs primary source validation | SEC EDGAR EBS Form 10-K; accession not retrieved | Tier 1 path | Measured, unretrieved | No |
| FY2024 operating margin | needs primary source validation | SEC EDGAR EBS Form 10-K; accession not retrieved | Tier 1 path | Measured, unretrieved | No |
| FY2024 net loss | needs primary source validation | SEC EDGAR EBS Form 10-K; accession not retrieved | Tier 1 path | Measured, unretrieved | No |
| NARCAN FDA approval | NDA 208411 | FDA, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208411, accessed 2026-04-26 | Tier 1 | Measured | Yes — FDA primary approval record |
| ACAM2000 FDA approval | NDA/STN 125158 | FDA, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125158, accessed 2026-04-26 | Tier 1 | Measured | Yes — FDA primary approval record |
_Pending primary-source company deep-dive._
Emergent’s product portfolio can be separated into commercial and government-focused countermeasures.
NARCAN (naloxone HCl) Nasal Spray
NARCAN is an opioid receptor antagonist. Its therapeutic function is to reverse opioid overdose by displacing opioid agonists from the mu-opioid receptor, rapidly restoring respiration. It is supplied as an intranasal spray. The FDA-approved product is designed for emergency administration by laypersons, first responders, and healthcare professionals.
Source: FDA NDA 208411 product page,
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208411
Accessed 2026-04-26. Document ID: NDA 208411; exact current label text must be verified at the FDA label link.
NARCAN’s OTC status and brand recognition are distribution assets, but the active pharmaceutical ingredient, naloxone, is off-patent. Generic competitors have developed naloxone nasal sprays, creating direct substitution risk.
ACAM2000 (smallpox/mpox vaccine)
ACAM2000 is a live, replication-competent vaccinia virus vaccine. It is administered percutaneously using a bifurcated needle. It is indicated for active immunization against smallpox in people at high risk for smallpox infection. Unlike the non-replicating Jynneos vaccine, ACAM2000 carries significant safety warnings, including myocarditis/pericarditis and risks in immunocompromised persons or those with certain skin conditions.
Source: FDA ACAM2000 product page,
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125158
Accessed 2026-04-26. Document ID: ACAM2000 approval/product information; exact current label text must be verified.
BioThrax and next-generation anthrax vaccine programs
BioThrax is an anthrax vaccine adsorbed used for pre-exposure prophylaxis against anthrax. Emergent has also worked on a next-generation anthrax vaccine, AV7909/NuThrax. The products serve the U.S. government’s Strategic National Stockpile and military biodefense requirements.
Source path: SEC EDGAR EBS Form 10-K index,
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367644&type=10-K&dateb=&owner=include&count=40
Accessed 2026-04-26. Document ID: most recent EBS Form 10-K; accession number not retrieved. Specific indications and stockpile contract status are needs primary source validation.
Other antibody-based countermeasures
Emergent markets antibody and antitoxin products, including:
- BAT — botulism antitoxin heptavalent.
- VIGIV — vaccinia immune globulin intravenous, for complications of vaccinia vaccination.
- Anthrasil — anthrax immune globulin intravenous.
These products treat rare but serious biothreat exposures. Their commercial markets are small, and demand is almost entirely government stockpiling and emergency use.
Source path: SEC EDGAR EBS Form 10-K index,
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367644&type=10-K&dateb=&owner=include&count=40
Accessed 2026-04-26. Document ID: most recent EBS Form 10-K; accession number not retrieved. Product names and current status are needs primary source validation.
- Naloxone: Competitive opioid receptor antagonist; rapid onset after intranasal administration; reverses life-threatening respiratory depression.
- ACAM2000: Replication-competent vaccinia vaccine; induces a protective immune response via controlled local infection.
- BioThrax/anthrax vaccines: Induce immunity against anthrax protective antigen.
- BAT/Anthrasil/VIGIV: Passive immunotherapy using antibodies against botulism toxin, anthrax toxin, or vaccinia.
The technical complexity of vaccine manufacturing and antibody purification is high, but the underlying science is not proprietary in the same way as a novel small molecule with composition-of-matter patents.
- NARCAN: Generic naloxone nasal spray from Teva, Hikma, Padagis, and others; injectable naloxone; higher-dose naloxone products; nalmefene-based overdose reversal agents. OTC naloxone availability reduces brand pricing power.
- ACAM2000: Bavarian Nordic’s Jynneos is a non-replicating smallpox/mpox vaccine with a preferred safety profile and is FDA-approved for both smallpox and mpox. Jynneos is the most direct competitive substitute for government smallpox/mpox vaccination programs.
- BioThrax: Antibiotics for post-exposure anthrax prophylaxis, next-generation anthrax vaccines, and other antitoxin products.
- BAT/Anthrasil/VIGIV: Alternative antibody products or supportive care depending on the indication.
Substitute sources: SEC EDGAR competitor filing index paths are listed in the “Contradictions” section and in Sources.
The business has real barriers, but they are not typical intellectual-property moats:
- Regulatory approvals: BLA/NDA approvals and FDA facility inspections are lengthy and costly.
- Biodefense contracting relationships: Long-term relationships with BARDA, HHS, CDC, and DoD create switching friction.
- Specialized manufacturing: Live vaccinia virus manufacturing, select-agent handling, aseptic fill-finish, and government-compliant quality systems are not trivial to replicate quickly.
- Stockpile acceptance: Emergency-use products must meet exacting government specifications and delivery schedules.
Source path: SEC EDGAR EBS Form 10-K index,
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367644&type=10-K&dateb=&owner=include&count=40
Accessed 2026-04-26. Document ID: most recent EBS Form 10-K; accession number not retrieved.
Pricing power is mixed and mostly limited.
- NARCAN: Low pricing power. Generic naloxone is available; the OTC shift increases price transparency and shopper comparison. Emergent likely cannot raise NARCAN prices without losing share to generics.
- Government MCM products: Moderate but contract-dependent. Sole-source products can maintain pricing under negotiated government contracts, but the U.S. government has significant buyer power and can choose alternatives or delay purchases.
- CDMO: Low pricing power while industry capacity is ample. Utilization-dependent service pricing is often under pressure.
Any specific price or margin assertion requires the latest Form 10-K and is needs primary source validation.
_Pending primary-source company deep-dive._
The thesis would be wrong, or materially weaker, if any of the following appears in primary filings or validated government disclosures:
- Loss of BARDA/HHS/DoD contracts. If the U.S. government cancels, delays, or recompetes Emergent’s core countermeasure contracts, revenue durability fails.
- Share shift to Bavarian Nordic’s Jynneos. If procurement data or competitor filings show Jynneos taking government smallpox/mpox purchases from ACAM2000, Emergent’s MCM franchise is structurally impaired.
- NARCAN price collapse. If generic naloxone manufacturers gain share and NARCAN realized price falls faster than expected, the commercial franchise’s unit economics deteriorate toward the adverse sensitivity scenarios above.
- CDMO utilization below breakeven. If Emergent’s manufacturing plants remain underutilized and pricing does not recover, fixed-cost absorption worsens and the services segment loses cash.
- Debt or covenant stress. If the 10-K or 10-Q shows imminent debt maturities, covenant pressure, or inability to refinance, the equity may face refinancing risk.
- Manufacturing-quality failures. Any new FDA Form 483, warning letter, import alert, or consent decree at an Emergent facility would directly attack the “hard to replicate” manufacturing-quality argument.
- Customer concentration worsens. If one government customer becomes an even larger share of revenue and that customer’s purchases are lumpy, the earnings stream becomes less predictable.
- Restructuring fails to improve margins. If the 10-K shows continued operating losses after asset sales, plant closures, or workforce reductions, the turnaround thesis weakens.
- COVID-era liabilities return. If the 10-K/10-Q discloses material new legal or contract liabilities from the COVID-19 CDMO terminations, cash flow and balance-sheet assumptions become unreliable.
- ACAM2000 safety or cold-chain limitations. If public-health agencies deprioritize ACAM2000 because of its live-virus safety profile or distribution complexity, Emergent’s smallpox vaccine franchise may not renew at historical levels.
INTACT (exposure surfaced from technology map; no capital allocation)
Primary and supporting material
Sources
9 sources preserved from the latest qualified research update.